APTOF · As filed with the SEC
Aptose Biosciences income statement, by quarter
The statement as Aptose Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 |
|---|---|---|---|---|
| Revenue | 0 | — | 0 | 0 |
| Operating expenses: | ||||
| Research and development | 3,621,000 | — | 2,205,000 | 3,298,000 |
| General and administrative | 3,561,000 | — | 2,708,000 | 3,623,000 |
| Total operating expenses | 7,182,000 | — | 4,913,000 | 6,921,000 |
| Other income (expenses): | ||||
| Other (expense) income, net | (19,000) | — | — | — |
| Interest expense, related party | (433,000) | — | — | — |
| Interest (expense) income | — | — | (212,000) | (110,000) |
| Foreign exchange loss | — | 1,000† | 2,000 | (12,000) |
| Total other expenses | (452,000) | — | (210,000) | (122,000) |
| Net loss and comprehensive loss | (7,634,000) | — | (5,123,000) | (7,043,000) |
| Unrealized loss on available-for-sale securities | — | — | — | 0 |
| Total comprehensive loss | — | — | — | (7,043,000) |
| Net loss per common share, basic | (2.99) | — | (2.01) | (2.76) |
| Net loss per common share, diluted | (2.99) | — | (2.01) | (2.76) |
| Weighted-average number of common shares outstanding, basic | 2,552,429 | — | 2,552,429 | 2,552,429 |
| Weighted-average number of common shares outstanding, diluted | 2,552,429 | — | 2,552,429 | 2,552,429 |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.